![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NRP1 |
Gene summary for NRP1 |
![]() |
Gene information | Species | Human | Gene symbol | NRP1 | Gene ID | 8829 |
Gene name | neuropilin 1 | |
Gene Alias | BDCA4 | |
Cytomap | 10p11.22 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | O14786 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8829 | NRP1 | LZE5T | Human | Esophagus | ESCC | 2.25e-05 | 3.64e-01 | 0.0514 |
8829 | NRP1 | LZE24T | Human | Esophagus | ESCC | 1.51e-10 | 3.03e-01 | 0.0596 |
8829 | NRP1 | P4T-E | Human | Esophagus | ESCC | 3.26e-05 | 5.28e-02 | 0.1323 |
8829 | NRP1 | P8T-E | Human | Esophagus | ESCC | 6.84e-15 | 3.84e-01 | 0.0889 |
8829 | NRP1 | P9T-E | Human | Esophagus | ESCC | 3.07e-13 | 3.31e-01 | 0.1131 |
8829 | NRP1 | P10T-E | Human | Esophagus | ESCC | 1.22e-06 | 6.30e-02 | 0.116 |
8829 | NRP1 | P11T-E | Human | Esophagus | ESCC | 4.82e-14 | 5.65e-01 | 0.1426 |
8829 | NRP1 | P21T-E | Human | Esophagus | ESCC | 1.19e-12 | 3.53e-01 | 0.1617 |
8829 | NRP1 | P23T-E | Human | Esophagus | ESCC | 3.67e-03 | 1.87e-01 | 0.108 |
8829 | NRP1 | P24T-E | Human | Esophagus | ESCC | 3.08e-07 | 2.96e-01 | 0.1287 |
8829 | NRP1 | P27T-E | Human | Esophagus | ESCC | 5.89e-04 | 3.26e-02 | 0.1055 |
8829 | NRP1 | P30T-E | Human | Esophagus | ESCC | 1.52e-14 | 5.34e-01 | 0.137 |
8829 | NRP1 | P31T-E | Human | Esophagus | ESCC | 2.14e-28 | 5.21e-01 | 0.1251 |
8829 | NRP1 | P32T-E | Human | Esophagus | ESCC | 2.86e-12 | 3.91e-01 | 0.1666 |
8829 | NRP1 | P36T-E | Human | Esophagus | ESCC | 5.97e-11 | 6.40e-01 | 0.1187 |
8829 | NRP1 | P37T-E | Human | Esophagus | ESCC | 2.89e-09 | 2.17e-01 | 0.1371 |
8829 | NRP1 | P40T-E | Human | Esophagus | ESCC | 4.11e-05 | 3.04e-01 | 0.109 |
8829 | NRP1 | P42T-E | Human | Esophagus | ESCC | 7.60e-04 | 1.34e-01 | 0.1175 |
8829 | NRP1 | P44T-E | Human | Esophagus | ESCC | 3.11e-05 | 2.51e-01 | 0.1096 |
8829 | NRP1 | P47T-E | Human | Esophagus | ESCC | 4.52e-05 | 1.31e-01 | 0.1067 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
GO:2001234111 | Esophagus | ESCC | negative regulation of apoptotic signaling pathway | 161/8552 | 224/18723 | 1.24e-15 | 8.09e-14 | 161 |
GO:2001236111 | Esophagus | ESCC | regulation of extrinsic apoptotic signaling pathway | 111/8552 | 151/18723 | 2.97e-12 | 1.18e-10 | 111 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
GO:0051099111 | Esophagus | ESCC | positive regulation of binding | 122/8552 | 173/18723 | 2.79e-11 | 9.45e-10 | 122 |
GO:004339320 | Esophagus | ESCC | regulation of protein binding | 135/8552 | 196/18723 | 3.69e-11 | 1.22e-09 | 135 |
GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
GO:0150115110 | Esophagus | ESCC | cell-substrate junction organization | 77/8552 | 101/18723 | 3.46e-10 | 9.57e-09 | 77 |
GO:000704418 | Esophagus | ESCC | cell-substrate junction assembly | 73/8552 | 95/18723 | 5.27e-10 | 1.35e-08 | 73 |
GO:0051701111 | Esophagus | ESCC | biological process involved in interaction with host | 135/8552 | 203/18723 | 1.49e-09 | 3.49e-08 | 135 |
GO:005149520 | Esophagus | ESCC | positive regulation of cytoskeleton organization | 147/8552 | 226/18723 | 2.93e-09 | 6.38e-08 | 147 |
GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517123 | Lung | AIS | Coronavirus disease - COVID-19 | 98/961 | 232/8465 | 2.82e-34 | 9.14e-32 | 5.85e-32 | 98 |
hsa0436021 | Lung | AIS | Axon guidance | 34/961 | 182/8465 | 2.22e-03 | 1.37e-02 | 8.80e-03 | 34 |
hsa0517133 | Lung | AIS | Coronavirus disease - COVID-19 | 98/961 | 232/8465 | 2.82e-34 | 9.14e-32 | 5.85e-32 | 98 |
hsa0436031 | Lung | AIS | Axon guidance | 34/961 | 182/8465 | 2.22e-03 | 1.37e-02 | 8.80e-03 | 34 |
hsa0517128 | Prostate | BPH | Coronavirus disease - COVID-19 | 115/1718 | 232/8465 | 5.65e-24 | 2.07e-22 | 1.28e-22 | 115 |
hsa05171113 | Prostate | BPH | Coronavirus disease - COVID-19 | 115/1718 | 232/8465 | 5.65e-24 | 2.07e-22 | 1.28e-22 | 115 |
hsa0517129 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
hsa0516629 | Prostate | Tumor | Human T-cell leukemia virus 1 infection | 78/1791 | 222/8465 | 7.99e-07 | 8.02e-06 | 4.97e-06 | 78 |
hsa0517137 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
hsa0516637 | Prostate | Tumor | Human T-cell leukemia virus 1 infection | 78/1791 | 222/8465 | 7.99e-07 | 8.02e-06 | 4.97e-06 | 78 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
SEMA3D | NRP1_PLXNA2 | SEMA3D_NRP1_PLXNA2 | SEMA3 | Breast | ADJ |
SEMA4A | NRP1_PLXNA4 | SEMA4A_NRP1_PLXNA4 | SEMA4 | Breast | DCIS |
SEMA3C | NRP1_PLXNA4 | SEMA3C_NRP1_PLXNA4 | SEMA3 | Breast | DCIS |
SEMA3D | NRP1_PLXNA4 | SEMA3D_NRP1_PLXNA4 | SEMA3 | Breast | DCIS |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Breast | DCIS |
SEMA3C | NRP1_PLXNA2 | SEMA3C_NRP1_PLXNA2 | SEMA3 | Breast | Healthy |
SEMA3D | NRP1_PLXNA2 | SEMA3D_NRP1_PLXNA2 | SEMA3 | Breast | Healthy |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Breast | Healthy |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Cervix | ADJ |
SEMA3C | NRP1_PLXNA2 | SEMA3C_NRP1_PLXNA2 | SEMA3 | Cervix | CC |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Cervix | CC |
SEMA4A | NRP1_PLXNA2 | SEMA4A_NRP1_PLXNA2 | SEMA4 | Cervix | CC |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | Cervix | Precancer |
SEMA3A | NRP1_PLXNA2 | SEMA3A_NRP1_PLXNA2 | SEMA3 | CRC | AD |
SEMA3C | NRP1_PLXNA2 | SEMA3C_NRP1_PLXNA2 | SEMA3 | CRC | AD |
SEMA3C | NRP1_NRP2 | SEMA3C_NRP1_NRP2 | SEMA3 | CRC | AD |
SEMA4A | NRP1_PLXNA2 | SEMA4A_NRP1_PLXNA2 | SEMA4 | CRC | AD |
SEMA4A | NRP1_PLXNA2 | SEMA4A_NRP1_PLXNA2 | SEMA4 | CRC | ADJ |
SEMA4A | NRP1_PLXNA4 | SEMA4A_NRP1_PLXNA4 | SEMA4 | CRC | ADJ |
SEMA3A | NRP1_PLXNA2 | SEMA3A_NRP1_PLXNA2 | SEMA3 | CRC | ADJ |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NRP1 | SNV | Missense_Mutation | c.1447N>A | p.Glu483Lys | p.E483K | O14786 | protein_coding | deleterious(0.02) | probably_damaging(0.933) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
NRP1 | SNV | Missense_Mutation | c.1591N>A | p.Asp531Asn | p.D531N | O14786 | protein_coding | deleterious(0.03) | probably_damaging(0.947) | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR | |
NRP1 | SNV | Missense_Mutation | c.1756G>A | p.Glu586Lys | p.E586K | O14786 | protein_coding | tolerated(0.41) | possibly_damaging(0.458) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
NRP1 | SNV | Missense_Mutation | c.878C>T | p.Ala293Val | p.A293V | O14786 | protein_coding | tolerated(0.06) | benign(0.02) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |
NRP1 | SNV | Missense_Mutation | c.2588N>T | p.Ala863Val | p.A863V | O14786 | protein_coding | tolerated(0.5) | possibly_damaging(0.841) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD | |
NRP1 | insertion | Nonsense_Mutation | novel | c.1004_1005insCTAATCAAAAGATTTCGGAGAATTCATACTCACCATCTCCCAGAA | p.Phe335_Val336insTer | p.F335_V336ins* | O14786 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
NRP1 | insertion | In_Frame_Ins | novel | c.2660_2661insAAAGCCCTGCTCTTTAATCAAACTCTGGTGGCC | p.Gly887_Met888insLysProCysSerLeuIleLysLeuTrpTrpPro | p.G887_M888insKPCSLIKLWWP | O14786 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
NRP1 | insertion | In_Frame_Ins | novel | c.2083_2084insTTTGTAATACACAGGGCACAGTCTCTTGCCTCAAAG | p.Ser695delinsPheCysAsnThrGlnGlyThrValSerCysLeuLysAla | p.S695delinsFCNTQGTVSCLKA | O14786 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
NRP1 | insertion | Frame_Shift_Ins | novel | c.724_725insCAGTGGTTTGGTTGTGGAAGATGCTGGGGGAAGCCAGTATGTTT | p.Ile242ThrfsTer27 | p.I242Tfs*27 | O14786 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
NRP1 | SNV | Missense_Mutation | novel | c.2522A>C | p.Lys841Thr | p.K841T | O14786 | protein_coding | tolerated(0.62) | benign(0.109) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8829 | NRP1 | DRUGGABLE GENOME | PEGAPTANIB | PEGAPTANIB SODIUM | ||
8829 | NRP1 | DRUGGABLE GENOME | ranibizumab | RANIBIZUMAB | 26426212 | |
8829 | NRP1 | DRUGGABLE GENOME | ANTI-NRP1 MAB | |||
8829 | NRP1 | DRUGGABLE GENOME | antagonist | 363894198 | ||
8829 | NRP1 | DRUGGABLE GENOME | Pegaptanib | PEGAPTANIB SODIUM | ||
8829 | NRP1 | DRUGGABLE GENOME | PALIFERMIN | PALIFERMIN | ||
8829 | NRP1 | DRUGGABLE GENOME | RG7347 | 26090340 |
Page: 1 |